ArticleScientific reports2025
Naringin mitigates experimental autoimmune prostatitis by modulating oxidative stress and the NLRP3 inflammasome via the PPAR-γ/NF-κB pathway.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Prostatitis-Related Male Infertility: From Inflammation and Dysbiosis to Sperm DNA Damage.Diagnostics (Basel, Switzerland) · 2026Review
- 4D-printed Fe3O4-PLLA scaffolds modulate osteoimmune microenvironment for oral bone repair.Materials today. Bio · 2026Article
- Nuclear receptor-driven immunometabolic crosstalk: immune-centric pharmacology targeting the inflamed nexus.Frontiers in cell and developmental biology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) is a debilitating condition characterized by pelvic pain and discomfort, necessitating the exploration of effective therapeutic strategies. This study aimed to elucidate the therapeutic potential of naringin (NAR) in addressing CP/CPPS by examining its role in modulating oxidative stress (OS) and the NLRP3 inflammasome via the PPARγ/NF-κB signaling pathway. Using both animal and cellular models of CP/CPPS, naringin was administered to mice with experimental autoimmune prostatitis (EAP), and the anti-inflammatory effect of naringin was assessed. Furthermore, cellular assays were performed to investigate the mechanistic pathway underlying the effects of naringin, with a focus on its role in mitigating oxidative stress and suppressing NLRP3 inflammasome activation. The results indicated that naringin significantly reduced inflammation in both models by effectively inhibiting NLRP3 inflammasome activation and restoring cellular homeostasis via oxidative stress modulation linked to the activation of the PPARγ/NF-κB axis. In conclusion, naringin showed promising therapeutic effects in mitigating inflammation associated with CP/CPPS, highlighting its potential as a novel treatment option. Further investigations into the clinical applicability of naringin are needed to fully understand its therapeutic potential in patients suffering from CP/CPPS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.